A new paper from MUSC Hollings Cancer Center researchers is helping to reveal the "rules" for engineering chimeric antigen receptor (CAR) Tregs. Tregs, or T-regulatory cells, have shown promise in ...

Discover how the ALA-CART platform enhances CAR T cell efficacy against antigen-low leukemias. With improved LAT activation, ...

A patient has achieved over 18 years of remission from neuroblastoma, a type of nerve cell cancer, following treatment with chimeric antigen receptor (CAR) T cell therapy and without requiring any ...

The research team hypothesized that binding of the antigen to the T-cell receptor would cause a conformational change, allowing it to initiate a downstream signaling cascade. By comparing an ...

The TCR increases the number and types of proteins available to surveilling T cells. Unlike a CAR, which only detects antigens expressed on the surface of a cell, a TCR can also access the ...

Although chimeric antigen receptor T-cell therapy has delivered previously unthinkable remission outcomes to patients with lupus and other rheumatic diseases, the cells currently in use remain ...

UK-based Enara said the funds will be used to develop its pipeline of T cell receptor (TCR)-based therapies ... can therefore present novel peptide antigens on their surface, coded by these ...

GPA33 antigen (colorectal cancer); GD2 antigen (neuroblastoma); and the HER2/neu receptor (breast cancer). Illustration of three-step DOTA-PRIT based on targeting with an IgG-scFv bispecific antibody ...